Moderna Inc MRNA shares are trading higher Tuesday after the company announced two new vaccine candidate developments.
Moderna will launch a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults. The new combination respiratory vaccine candidate, mRNA-1230, would act as an annual booster targeting SARS-CoV-2 virus, influenza virus and respiratory syncytial virus.
Moderna also introduced a program to develop vaccine candidate mRNA-1287 against endemic human coronaviruses. Four human coronaviruses are endemic globally, accounting for approximately 10% to 30% of upper respiratory tract infections in adults.
See Also: Why Society Pass Shares Are Surging
MRNA 52-Week Range: $117.34 - $497.49
Moderna Shares were up 5.78% at $185.49 at time of publication.
Photo: mufidpwt from Pixabay.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.